Market revenue in 2023 | USD 364.3 million |
Market revenue in 2030 | USD 477.2 million |
Growth rate | 3.9% (CAGR from 2023 to 2030) |
Largest segment | Stimulants |
Fastest growing segment | Non-stimulants |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Stimulants, Non-stimulants |
Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Johnson & Johnson, Lupin, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Mallinckrodt PLC Ordinary Shares - New, Vital KSK Holdings Inc, NeuroSense Therapeutics Ltd, Supernus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to attention deficit hyperactivity disorder market will help companies and investors design strategic landscapes.
Stimulants was the largest segment with a revenue share of 70.96% in 2023. Horizon Databook has segmented the Germany attention deficit hyperactivity disorder market based on stimulants, non-stimulants covering the revenue growth of each sub-segment from 2018 to 2030.
Germany accounts for the largest share of the Europe attention deficit hyperactivity disorder market. The etiology of the disease is multifactorial, complex, and not yet fully understood. There is a genetic disposition, which is reflected in a familial accumulation of the disease.
The first choice of treatment prescribed in Germany is Ritalin in small doses, i.e., 5-10mg. The dose is increased progressively based on feedback from the patient. Methylphenidate was prescribed most frequently, followed by atomoxetine and lisdexamfetamine.
The pathogenesis of ADHD is not fully understood. The medical guideline recommends stimulants Ritalin (methylphenidate), amfetamine, and lisdexamfetamine) and nonstimulants (atomoxetine and guanfacine) as drug therapy in patients with ADHD. The approval status must be observed in each case. It must also be noted that stimulants are prescription narcotics under the Narcotics Act.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany attention deficit hyperactivity disorder market , including forecasts for subscribers. This country databook contains high-level insights into Germany attention deficit hyperactivity disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account